Beximco Pharmaceuticals Ltd Notice of Preliminary Results and AGM (6276U)
26 October 2017 - 5:00PM
UK Regulatory
TIDMBXP
RNS Number : 6276U
Beximco Pharmaceuticals Ltd
26 October 2017
BEXIMCO PHARMACEUTICALS LTD.
26 October 2017
Notification of Preliminary Results and Annual General
Meeting
Beximco Pharmaceuticals Ltd. ("BPL", "Beximco Pharma" or
"Company"; AIM Symbol: BXP), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical
ingredients, today announces information for the shareholders of
the Company that the Board of Directors at their meeting held on
25(th) October, 2017 has decided the following:
1. To recommend the approval : The Audited Financial
of the Financial Statements Statements for the
for the year ended 30 year ended 30 June 2017
June 2017 have been
approved. The full accounts
are expected
to be announced by 6
November 2017
--- ----------------------------- -----------------------------
2. Date & Time of 41(st) : 23 December 2017 at 10.00
AGM of the Company for am
the year ended 30 June
2017
--- ----------------------------- -----------------------------
3. Venue of AGM : Beximco Industrial Park,
Sarabo, Kashimpur, Gazipur,
Bangladesh
--- ----------------------------- -----------------------------
4. Proposed Dividend for : 12.5% Cash Dividend (i.e.
the year ended 30 June Tk.1.25 per share)
2017
--- ----------------------------- -----------------------------
5. Record date : 15 November 2017
--- ----------------------------- -----------------------------
6. Net Asset Value as at : Taka 25,072,425,900
30 June 2017
--- ----------------------------- -----------------------------
7. Net Asset Value per : Taka 61.82
Share as at 30 June
2017
--- ----------------------------- -----------------------------
8. Earnings per share (EPS) : Taka 5.49
for the year ended 30
June 2017
--- ----------------------------- -----------------------------
9. Net Operating Cash Flow : Taka 6.49
per share for the year
ended 30 June 2017
--- ----------------------------- -----------------------------
For further information please visit www.beximco-pharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company
Secretary
Tel; +880 2 58611891, +880 2 58612040, Ext 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Sean Wyndham-Quin
Tel: +44 (0)20 3368 3551 / 3555
Northland Capital Partners Limited (Broker)
Gerry Beaney / Tom Price
Tel: +44 (0)20 3861 6625
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma
manufactures and sells generic pharmaceutical formulation products
and active pharmaceutical ingredients. The Company also undertakes
contract manufacturing for multinational and leading global generic
pharmaceutical companies. The Company operates from a 23 acre site
in Dhaka and has manufacturing facilities for producing various
drugs in different delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, prefilled syringes,
injectables, nebuliser solutions, oral soluble films etc. Ensuring
access to quality medicines is the powerful aspiration that
motivates 3,500 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others. The
Company's products are sold to retail outlets, medical institutions
and other pharmaceutical manufacturers in Bangladesh, in regional
markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and
Myanmar and in other markets overseas, principally in South East
Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia,
Philippines and Hong Kong; Africa, including South Africa,
Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central
Asia, including Azerbaijan; Middle East, including Kuwait and
Jordan; Pacific Island countries; Latin and Central American
countries; Europe, including Austria, Germany and Romania;
Australia and North America, including the USA and Canada.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORZELFLDBFZFBX
(END) Dow Jones Newswires
October 26, 2017 02:00 ET (06:00 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Apr 2024 to May 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From May 2023 to May 2024